Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-29

Clinical Trial Update: Study of Atorvastatin Dose Dependent Reduction of Proteinuria [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether atorvastatin reduces proteinuria in chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lipitor (atorvastatin)

Snippet

Sponsor: Laval University | Conditions: Chronic Kidney Disease | Phase 4 | Status: COMPLETED